---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-061973"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-09-15T12:31:45+00:00"
generated_at: "2026-09-15T12:35:11.568785+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioMarin discontinues VOXZOGO development for Noonan syndrome

## Summary
- Decision announced Sept 15, 2026; development halted for Noonan syndrome indication.
- Cites study feasibility and current treatment landscape as reasons.
- Company states decision not related to safety or efficacy of VOXZOGO.

## SEC filing metadata
- accession: 0001628280-26-061973
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-09-15T12:31:45+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/0001628280-26-061973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-061973
- JSON: https://secwatch.observer/filing/0001628280-26-061973.json
- Plain text: https://secwatch.observer/filing/0001628280-26-061973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.